Evaluating Cognitive Tasks and Brain Activity in Schizophrenia and Schizoaffective Disorder Compared to Healthy Adults
Led by Washington University School of Medicine · Updated on 2026-10-02
325
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying schizophrenia, schizoaffective disorder, and healthy adult participants to understand how different cognitive tasks can distinguish between these groups and predict symptoms like hallucinations and delusions. The study aims to compare seven specific behavioral tasks and validate their results against brain activity measured by EEG. The goal is to find out if hallucinations and delusions come from separate or shared processes and to improve assessment methods for psychotic disorders.
Participants will complete four sessions over approximately three weeks, each lasting about three hours. During these sessions, they will undergo clinical assessments, self-reports, and perform seven different cognitive tasks while their brain activity is recorded with a 64-channel EEG. The tasks include motion perception, speech processing, learning prediction errors, and trust game activities. The first session focuses on clinical and functional evaluations, while the next three sessions involve task performance with EEG recording.
Throughout the study, participants will be evaluated using various clinical interviews and symptom rating scales to measure hallucination and delusion severity, mood, anxiety, motivation, and community functioning. Cognitive ability will also be assessed using validated online tests. EEG data will be processed to analyze brain responses during the tasks. Researchers will measure task performance across all seven tasks to understand cognitive differences and their relation to psychotic symptoms. The total participation lasts about three weeks, with multiple assessments and EEG recordings.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Investigational computational cognitive tasks
Standard clinical cognitive battery
What it is
A series of computer-based cognitive tasks designed to probe specific domains of belief updating, prediction error processing, sensory precision, and reinforcement learning.
A validated clinical cognitive battery (such as MCCB) composed of standardized neuropsychological tests covering attention, memory, processing speed, executive function, and other domains.
Primary use
To advance understanding of cognitive processes underlying schizophrenia and schizoaffective disorder using detailed computational modeling and behavioral paradigms.
To quantify cognitive deficits in schizophrenia and schizoaffective disorder for clinical diagnosis, treatment planning, and clinical trial eligibility.
How it is given or performed
Participants complete a series of computerized tasks assessing motion perception, speech detection, volatility, reversal learning, trust evaluation, and blocking, generally in a single testing session.
Participants undergo standardized tests (e.g., MCCB) administered by trained staff, typically lasting about 1 to 2 hours in a clinical or research setting.
Evidence status
The task battery is being actively studied; evidence for clinical utility is still emerging, with ongoing research evaluating reliability, replicability, and clinical applications.
The MCCB is validated as a clinical cognitive assessment tool with robust evidence supporting its reliability and utility in schizophrenia and schizoaffective disorder populations.
Important limitations
The neurocomputational task battery is investigational, and its clinical relevance is not yet established; it may not capture all cognitive domains needed for clinical decision-making. Tasks may require specialized research environments and staff, limiting accessibility.
Standard batteries like MCCB primarily assess broad cognitive abilities and may miss subtle domain-specific deficits. Cultural/language biases and test-retest learning effects are known limitations.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 59Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Age between 18 and 59 years
No substance use disorder in the past six months confirmed by urine drug screens and breathalyzers
No clinically significant head injury or neurological disease
Wechsler Test of Adult Reading (WTAR) score of 16 or higher
For schizophrenia/schizoaffective disorder group: diagnosis by DSM-5 criteria
No medication changes in the past month or anticipated in the next month, or currently unmedicated
Outpatient or partial hospital status if unmedicated
For healthy controls: no DSM-5 diagnosis of psychosis or bipolar disorder
No family history of psychosis or bipolar disorder
You will not qualify if you...
For healthy controls: diagnosis of psychosis or bipolar disorder
Family history of psychosis or bipolar disorder
For unmedicated schizophrenia/schizoaffective disorder patients: acute exacerbation requiring immediate hospitalization or treatment
Self-reported medication non-compliance for at least the previous four weeks
Never having started medications
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Assessment and Testing
Duration - Approximately 3 weeks
Participants complete four sessions over about three weeks, including clinical interviews, self-report questionnaires, and seven cognitive tasks while EEG is recorded.
4 sessions lasting about 3 hours each
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
0
Similar Trials
Multi-Session 40 Hz Visual Stimulation to Improve Brain Activity and Symptoms in Schizophrenia
Testing Safety, Tolerability, and Pharmacokinetics of CPV-104 in Healthy Adults and Patients With C3-Glomerulopathy
Study of ARD001 for Safety and Tolerability in Healthy Men and Adults With Hemophilia A Using Single and Multiple Doses
Safety and Pharmacokinetics Study of HMB-003 Drug in Healthy Adults Aged 18 to 50
Phase 1 Study Evaluating Drug Interactions and Heart Effects of Fosmanogepix in Healthy Adults
Study of Three Doses of Cobenfy Xanomeline and Trospium Using PETMRI to Measure Dopamine Changes in Adults with Schizophrenia
Pharmacokinetic and Safety Study of Oral D-2570 in Adults With Liver Impairment and Normal Liver Function
Phase 1 Study to Evaluate Safety, Tolerability, and Drug Interactions of TBD11 in Healthy Adults with Up to 84 Days of Daily Dosing
Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of NS-079 Compared to Placebo in Healthy Adults
Evaluating the Effectiveness of Fish Oil and Algae Oil Supplements on Omega-3 Levels in Healthy Adults with Low Fatty Fish Intake
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder.
Functional and Neuroanatomic Specificity of Episodic Memory Dysfunction in Schizophrenia: A Functional Magnetic Resonance Imaging Study of the Relational and Item-Specific Encoding Task.
J Daniel Ragland, Charan Ranganath, Michael P Harms...